Drug Database
ES

estradiol valerate + MPA (Divina / E2V + MPA, Orion / Klimalet)

✓ Approved

HyundaiPharm · ESR1 · Small Molecule

What is estradiol valerate + MPA?

estradiol valerate + MPA is a small molecule developed by HyundaiPharm. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesDivina, E2V + MPA, Orion, Klimalet
CompanyHyundaiPharm
Drug ClassSmall Molecule
Molecular TargetESR1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, HyundaiPharm

Mechanism of Action

Molecular Targets

estradiol valerate + MPA acts on 1 molecular target:

ESR1estrogen receptor 1 (ER, ESR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

estradiol valerate + MPA is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresHormone replacement therapy✓ Approved

Related Research Articles

PubMedOpen research Europe2026-09-20

Moderate and vigorous physical activity show intensity specific familial and interpersonal association patterns in 9-12-year-olds: A cross-sectional DE-PASS study.

Ferreira Flávio F, Dowd Kieran K, Coffey Alan A, Cardon Greet G et al.

Research on children's physical activity often examines interpersonal associations but commonly aggregates MPA and VPA into a single MVPA outcome. This approach may obscure intensity-specific association patterns, particularly in intergenerational analyses. This cross-sectional study used harmonized data from the European DE-PASS project, including children aged 9-12 years and one of their parents. Waist-worn accelerometry was used to assess MPA and VPA. Perceived parental, peer, and teacher support were measured using validated questionnaires. Intensity-specific associations between parent and child physical activity and between interpersonal support variables and children's activity were examined, including sex-stratified and socioeconomic sensitivity analyses. Parent-child associations differed by activity intensity. Parent-child resemblance was numerically larger for MPA than for VPA, although the difference between intensities was not statistically significant when formally compared; associations involving VPA were weaker and less consistent. Parental co-participation support showed a weak positive association (which did not survive correction for multiple testing) with children's MPA, whereas peer and teacher support showed limited or no associations with children's activity at either intensity. Sex-stratified analyses indicated similar MPA associations across boys and girls, while associations for VPA were not observed among girls. Aggregating MPA and VPA into MVPA may obscure these intensity-specific patterns. These findings indicate that interpersonal associations with children's physical activity differ by intensity and support examining MPA and VPA as intensity-specific outcomes in intergenerational analyses. Family-based approaches focusing on MPA may represent a pausible direction for future longitudinal and intervention research, while different strategies may be needed to address VPA.

PMID 42763449
Read full article →
PubMedCureus2026-09-20

Comparative Analysis of Bond Strength in Endodontic Access: Immediate Endodontic Sealing Versus Delayed Endodontic Sealing.

Buranakarn Thanyaporn T, Tantilertanant Yanee Y, Tagami Junji J, Pimkhaokham Somsinee S

Coronal leakage and restoration failure remain significant contributors to the failure of endodontic treatments. This study aimed to evaluate the influence of different adhesive systems and treatment protocols, specifically immediate endodontic sealing (IES) and delayed endodontic sealing (DES), on bond strength. Sixty extracted human mandibular third molars were prepared to expose the pulp chamber dentin and randomly assigned to six groups according to the adhesive systems (OptiBond™ FL (Kerr Dental, California, United States) or Single Bond Universal adhesive (Solventum Corporation, Eagan, Minnesota, United States)) and the treatment protocols (control, IES, and DES). Sodium hypochlorite irrigation was performed based on experimental protocols. Following composite restoration, specimens were thermocycled for artificial aging and subsequently sectioned into beams for microtensile bond strength (µTBS) testing (10 teeth per group). Data were analyzed using two-way ANOVA and Kruskal-Wallis with Dunn's post hoc test (α = 0.05). A significant interaction between adhesive system and treatment protocol was identified (p < 0.05). With OptiBond FL, IES produced significantly higher µTBS values than DES (52.85 ± 7.22 MPa vs 40.98 ± 5.76 MPa; p < 0.05) and was comparable to the control group (57.59 ± 7.18 MPa; p > 0.05). The OptiBond FL group demonstrated significantly higher bond strength than the Single Bond Universal group under all conditions (p < 0.05), whereas the IES-Single Bond Universal adhesive (34.43 ± 5.97 MPa) and DES-Single Bond Universal adhesive (30.27 ± 5.49 MPa) groups showed significantly lower µTBS values than the control-Single Bond Universal adhesive (41.12 ± 4.85 MPa; p < 0.05). Failure mode analysis revealed predominantly adhesive failures in all groups. Within the limitations of the in vitro study, IES with OptiBond FL resulted in higher µTBS than DES.

PMID 42763528
Read full article →
PubMedBMC musculoskeletal disorders2026-09-20

Optimized anterior anatomical fusion plate for ankle arthrodesis: biomechanical and clinical outcomes.

Liu Yi Y, Ruan Yaokuan Y, Jiang Zhende Z, Hu Shichen S et al.

Ankle osteoarthritis (OA) is a common degenerative joint disorder that often necessitates ankle arthrodesis. Conventional fusion methods may offer limited fixation stability and require extensive soft-tissue exposure. The goal of this study was to evaluate the biomechanical properties of a geometrically optimized anterior anatomical fusion plate (AAFP) for ankle arthrodesis, which has been designed to enhance mechanical performance and minimize surgical trauma. This study developed a finite element model of the ankle based on CT scans of a healthy male volunteer. Various fusion models were created, incorporating the optimized AAFP with or without transarticular screw, anterolateral fusion plate (ALFP) with or without transarticular screw, and configurations using three or two screws. The biomechanical performance of these systems was assessed by analyzing peak displacement of the fusion surface and peak von Mises stress of implants and bone-implant models under seven common ankle postures. Additionally, the preliminary feasibility of the optimized AAFP was assessed by analyzing the American Orthopaedic Foot & Ankle Society (AOFAS) scores and X-ray images. The optimized AAFP with transarticular screw fixation exhibited great stability, with peak displacement of 0.14 mm in neutral position, 0.19 mm in dorsiflexion, 0.07 mm in plantar flexion, 0.09 mm in internal rotation, 0.07 mm in external rotation, 0.10 mm in inversion, and 0.12 mm in eversion. The peak stress of the fusion method was relatively low, with 132.91 MPa in neutral position, 145.83 MPa in dorsiflexion, 97.15 MPa in plantar flexion, 84.27 MPa in internal rotation, 74.70 MPa in external rotation, 98.07 MPa in inversion, and 88.00 MPa in eversion. The transarticular screw enhanced biomechanical stability of the optimized AAFP in ankle fusion by reducing stress and displacement. Clinically, the optimized AAFP showed satisfactory short-term outcomes, with improvements in the AOFAS scores (from 53 to 83, 57 to 82, 51 to 84 and 57 to 83) and imaging results. These findings suggest that the geometrically optimized AAFP combines a smaller incision with favorable biomechanical performance and warrants further clinical evaluation as a potential option for ankle fusion.

PMID 42763403
Read full article →
PubMedUrologie (Heidelberg, Germany)2026-09-20

[Gender-affirming hormone therapy: state of the art].

Bischoff Jenny J

Gender incongruence affects approximately 0.6% of the population in Germany and, when accompanied by significant psychological distress, may constitute an indication for gender-affirming hormone therapy (GAHT). The increasing diversity of gender identity has led to a more individualized approach to hormone therapy. The decision to initiate treatment is based on the expected reduction in gender-related dysphoria due to hormonal treatment. Treatment is carried out in accordance with guidelines and is tailored to the wishes and goals of the person seeking treatment. Various estradiol preparations and antiandrogenic substances can be used to achieve feminization. Masculinizing therapy relies primarily on testosterone. For non-binary individuals, GAHT is usually administered at lower doses and typically focuses on specific aspects of gender alignment. The therapeutic effects usually develop slowly but can be irreversible and significant. Risks should be assessed in advance, and patients should be informed about potential adverse effects. Monitoring and adjustment of treatment take place at specified regular intervals. Adjustments and support throughout the course of treatment-ranging from fertility preservation to cancer screening-are key components of comprehensive care in patients undergoing GAHT. Although the evidence regarding GAHT has improved significantly in recent years, large-scale studies are still lacking for many aspects.

PMID 42763335
Read full article →
PubMedEndocrine regulations2026-09-19

Estrogens hypersensitivity syndrome in endometriosis.

Rukhliada Nikolai Nikolaevich NN, Dudova Kristina Andreevna KA

Objectives. The aim of the study was to develop a diagnostic method for estrogen hypersensitivity syndrome in proliferative benign diseases of the female reproductive system. Using the example of endometriosis, changes in the activity of the chaperone protein Hsp90α were determined as a diagnostic biomarker. Methods. The study included 60 women aged 30 to 50 years, thirty of whom had a laparoscopically confirmed diagnosis of endometriosis and 30 were included in the control group. After blood sampling to determine the baseline levels of Hsp90α, the patients were prescribed a single oral dose of estradiol valerate 2 mg tablet. The plasma Hsp90α levels were remeasured 6 h later. Results. No significant change (p>0.05) in baseline Hsp90α concentrations was found between the group of patients with endometriosis and the control group. Six hours after estradiol valerate administration, a significant difference (p<0.001) in Hsp90α levels was observed between the group of patients with endometriosis and the control group. The increase in Hsp90α concentration following the test-load was also more pronounced in women with confirmed endometriosis compared to controls (27.29±15.62 ng/ml and 3.16±4.36 ng/ml, respectively) (p<0.001). ROC analysis indicated that the absolute increase in Hsp90α level of more than 8.6 ng/ml in patients with endometriosis has a sensitivity of 0.93 and a specificity of 0.97 (compared to the control group). This change in relative concentration corresponded to an increase of over 28.7%. Conclusion. The increase in Hsp90α plasma level of more than 30% within 6 h after the test-load is a specific criterion for estrogen hypersensitivity syndrome in endometriosis. Further investigation including other nosological forms (myoma, adenomyosis, endometrial hyperplasia) is required.

PMID 42762506
Read full article →
PubMedJournal of stomatology, oral and maxillofacial surgery2026-09-19

Posterior Implant Tilt as an Alternative to Sinus Elevation in Full-Arch Maxillary Rehabilitation: A Comparative Finite Element Analysis.

Oğuz Elif Ezgi EE, Erdil Aras A, İğneci Mehmet M

This finite element analysis study aimed to compare the stress distributions in cortical and trabecular bone, implants, abutments, and prosthetic components under anterior and posterior loading in three different implant configurations, including maxillary sinus grafting, in a completely edentulous and posteriorly atrophic maxilla. The study specifically focused on identifying the differences between a prosthetic design with a distal cantilever after maxillary sinus lift (Model 3) and configurations without a cantilever, featuring posteriorly angled implants with different exit points (Models 1 and 2). An atrophic maxillary model was reconstructed from computed tomography images obtained from a publicly available online database. Each study model utilized six Straumann BL Roxolid implants, with a screw-retained cobalt-chromium alloy prosthetic substructure. In each model, the implants were placed vertically anterior to the maxillary sinus; Model 1 featured a distally angled implant with its exit point at the second molar, Model 2 included a tuberoid implant connected to the prosthetic substructure with a distal extension, and Model 3 featured an axial implant placed at the level of the first molar after sinus grafting. All models were subjected to a foodstuff-style force of 100 N in the anterior and posterior regions. Maximum principal stress (σ_max), minimum principal stress (σ_min), and von Mises stress were recorded in the implant, periimplant bone, and prosthetic components. Under anterior loading, Model 3 produced the highest peak stresses in the framework (33.218 MPa), implant (15.444 MPa), abutment (21.247 MPa), and cortical bone (maximum principal stress, 3.874 MPa; minimum principal stress, -4.017 MPa). Under molar loading, Model 3 produced the highest framework, implant, and abutment stresses (54.844, 33.259, and 49.019 MPa, respectively) but lower posterior cortical stresses (maximum principal stress, 3.319 MPa; minimum principal stress, -6.453 MPa) than Model 1 (6.524 and -13.243 MPa) and Model 2 (7.641 and -13.327 MPa). No configuration minimized stress in every structure. The graftless configurations reduced selected prosthetic stresses but transferred greater demand to posterior cortical bone, whereas the sinus-grafted configuration reduced posterior cortical stress while increasing mechanical demand in the cantilevered prosthetic complex. Treatment planning should therefore consider the distribution of biomechanical demand across the entire bone-implant-prosthesis system rather than a single peak value.

PMID 42762978
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about estradiol valerate + MPA